Measuring the Impact of NSFs and NICE Guidance
Friday 14th December, 2001
Royal Society of Medicine, London

• Monitoring and Managing the inplications of the CHD NSFs

Mr Tom Quinn, Project Manager, Department of Health

• Using GPRD to support delivery of the NHS National Plan

Dr Louise Wood, Manager, GPRD Project, Medicines Control Agency

• CHI – Implications for Primary Care and Prescribing
  

Mrs Jocelyn Cornwell, Director of Policy & Development, Commission for Health Improvement

• Co-prescribing with nitrate therapy shows selective neglect of women in secondary prevention in Ireland

Dr David Williams, Lecturer in Clinical Pharmacology & Therapeutics, St James’s Hospital, Dublin

• A qualitative study to ascertain how a PCG is responding to the NSF for CHD
  

Ms Maria Allinson, Senior Primary Care Pharmacist, Central & South Knowsley PCG

• Linking the NSF for older people & the NSF for CHD in practice

Mrs Jenny Harding, PCG Pharmacist, Rowley Regis & Tipton PCG

• A review of statin prescribing in general practice in England 1993-1998
  

Mr Keith Farrar, Pharmacy Dept., Wirral Hospital NHS Trust

• Does economic evaluation affect pharmaceutical decision-making?

Dr Andrew Walker, Senior Lecturer in Health Economics, University of Glasgow

• Proton Pump inhibitor prescribing patterns in a District General Hospital
  

Dr Chris Langley, Lecturer in Pharmacy Practice, Aston University

PCT Perspective
Mrs Eleri de Gilbert, Chief Executive, Mansfield PCT
Ms Christine Lawson, Prescribing Adviser, Mansfield PCT